LabGenius, founded in 2012 by James Field, is a biopharmaceutical company that utilises a machine learning-driven evolution engine (EVA™) to develop next-generation protein therapeutics. Their platform integrates advanced technologies from machine learning, synthetic biology, and robotics.

Initially, LabGenius applies this platform to rapidly discover and enhance novel therapeutic antibodies, targeting cancer and inflammatory diseases.

Their platform has already demonstrated success in co-optimising mono- and multi-specific single domain antibodies, enhancing properties such as stability, potency, and cell selectivity.

In tandem with collaborative projects, LabGenius is actively advancing its internal pipeline, with a focus on discovering and refining immunotherapeutics. 

LabGenius Executive Team

• James Field, Founder & Chief Executive Officer
• Leonard Wossnig, Chief Technology Officer
• Gino Van Heeke, Chief Scientific Officer

LabGenius Advisory Board

• Hendrik-Tobias Arkenau, CMO and Global Head of Pharma, Ellipses Pharma
• Victor Greiff, Associate Professor, University of Oslo
• Patrick Pichette, Partner at Inovia
• Chris Gibson, Founder & CEO, Recursion
• Aaron Kimball, Head of Engineering, Benchling